Overview
Tay-Sachs disease (infantile form) is a severe inherited condition that affects the brain and nervous system. It is also known as GM2 gangliosidosis type 1 or hexosaminidase A deficiency. In this disease, the body lacks an important enzyme called hexosaminidase A (Hex-A), which is needed to break down a fatty substance called GM2 ganglioside in nerve cells. Without this enzyme, GM2 ganglioside builds up in the brain, progressively destroying nerve cells. Babies with infantile Tay-Sachs disease usually appear healthy at birth and develop normally for the first few months of life. Around 3 to 6 months of age, parents may notice their baby becoming less responsive, having difficulty with movements, and showing an exaggerated startle reaction to loud sounds. A distinctive cherry-red spot can be seen in the back of the eye during an eye exam. Over time, the child loses previously learned skills such as sitting, crawling, and turning over. Seizures, vision loss, and difficulty swallowing develop as the disease progresses. Unfortunately, there is currently no cure or disease-modifying treatment for infantile Tay-Sachs disease. Care focuses on keeping the child as comfortable as possible and managing symptoms such as seizures, feeding difficulties, and respiratory problems. Research into gene therapy, enzyme replacement therapy, and substrate reduction therapy is ongoing, offering hope for future treatments. The disease follows a progressive course, and most children with the infantile form pass away in early childhood, typically between ages 3 and 5.
Also known as:
Key symptoms:
Exaggerated startle response to loud noisesLoss of previously learned skills (developmental regression)Inability to sit, crawl, or roll overCherry-red spot in the back of the eyeProgressive vision loss leading to blindnessSeizuresDifficulty swallowing and feedingMuscle weakness and floppinessLater development of muscle stiffness and spasticityIncreasing head size (macrocephaly)Loss of awareness and responsivenessBreathing and respiratory difficultiesIntellectual disability
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Tay-Sachs disease, infantile form.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Tay-Sachs disease, infantile form at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Tay-Sachs disease, infantile form.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Tay-Sachs disease, infantile form.
Community
No community posts yet. Be the first to share your experience with Tay-Sachs disease, infantile form.
Start the conversation →Latest news about Tay-Sachs disease, infantile form
No recent news articles for Tay-Sachs disease, infantile form.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the expected timeline for how my child's condition may change?,Are there any clinical trials or experimental treatments that my child might be eligible for?,When should we consider placing a feeding tube, and what are the benefits and risks?,What seizure medications are best for my child, and what side effects should I watch for?,How can we access palliative care services to help manage my child's comfort?,Should other family members or future pregnancies be tested for carrier status?,What support services are available for our family, including siblings and caregivers?
Common questions about Tay-Sachs disease, infantile form
What is Tay-Sachs disease, infantile form?
Tay-Sachs disease (infantile form) is a severe inherited condition that affects the brain and nervous system. It is also known as GM2 gangliosidosis type 1 or hexosaminidase A deficiency. In this disease, the body lacks an important enzyme called hexosaminidase A (Hex-A), which is needed to break down a fatty substance called GM2 ganglioside in nerve cells. Without this enzyme, GM2 ganglioside builds up in the brain, progressively destroying nerve cells. Babies with infantile Tay-Sachs disease usually appear healthy at birth and develop normally for the first few months of life. Around 3 to 6
How is Tay-Sachs disease, infantile form inherited?
Tay-Sachs disease, infantile form follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Tay-Sachs disease, infantile form typically begin?
Typical onset of Tay-Sachs disease, infantile form is infantile. Age of onset can vary across affected individuals.